Virbac Revenue Climbs 7.4% on Strong Supercharge Platform Demand
Animal health company Virbac reported first-half 2026 revenue of €768 million, marking a 7.4% increase at constant exchange rates. This growth, fueled by a 12% surge in the firm’s Supercharge product platforms, keeps the company on track to hit the top end of its annual financial targets.
The balanced performance saw companion animal sales rise by 10%, while the farm animal segment grew by 6.7%. Management attributed the results to a combination of volume and mix effects contributing 5.4% to the total, supplemented by a 2% price increase. The recent acquisition of Thyronorm proved significant, accounting for 1.4 percentage points of the overall growth.
Geographically, North America led the expansion with double-digit gains, successfully offsetting temporary hurdles in toll manufacturing. European and international markets followed with growth rates of 6.5% and 7.5% respectively. CEO Paul Martingell highlighted the resilience of the portfolio against a difficult external backdrop, noting that the integration of Thyronorm has already begun to generate commercial synergies in the endocrinology sector. Based on these figures, Virbac confirmed its full-year guidance, targeting the upper bound of its 5.5% to 7.5% revenue growth range and an adjusted recurring operating income margin near 17%.
Comments (0)
No comments yet. Be the first!